Cempra (CEMP) : Fridays money flow points at investors jumping to buy the stock on the weakness of price. $3.64 million worth of transactions were on upticks, whereas, the downticks accounted for $2.65 million worth of transactions. The net money flow was a positive $0.98 million and the uptick to downtick ratio was 1.37. However, the block trades showed a clear dominance of the bulls with a very healthy ratio of 4.76 in their favor. The net money flow into the stock was $0.83 million. The value of block trades done on downticks was only $0.22 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $1.04 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Cempra (CEMP) was trading at $22.1, down $0.19 during day. The stock slid -0.85% over the previous days close. For the week, the stock recorded 3.76% over the previous weeks close.
The company Insiders own 17.8% of Cempra shares according to the proxy statements. Institutional Investors own 79.17% of Cempra shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the officer (Chief Commercial Officer) of Cempra, Inc., Moore David had purchased shares worth of $8,090 in a transaction dated on March 1, 2016. A total of 500 shares were purchased at a price of $16.18 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Cempra (NASDAQ:CEMP): stock was range-bound between the intraday low of $21.8 and the intraday high of $22.4445 after having opened at $22.21 on Fridays session. The stock finally closed in the red at $22.21, a loss of -0.81%. The stock remained in the red for the whole trading day. The total traded volume was 592,475 shares. The stock failed to cross $22.4445 in Fridays trading. The stocks closing price on Thursday was $22.29.
Cempra (CEMP) has been under a strong bear grip, hence the stock is down -8.29% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.28% in the past 1 week. The stock has risen by 3.8% in the past week indicating that the buyers are active at lower levels, but the stock is down -8.41% in the past 4 weeks.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.